AAPL337.28+0.26 (+0.08%) ▲|ABBV265.27+0.19 (+0.07%) ▲|ABT101.11-2.38 (-2.30%) ▼|ACN178.00-5.52 (-3.01%) ▼|ADBE238.12-2.57 (-1.07%) ▼|AMAT473.60-0.79 (-0.17%) ▼|AMD627.90+13.29 (+2.16%) ▲|AMGN407.83+1.74 (+0.43%) ▲|AMT168.27-2.52 (-1.47%) ▼|AMZN249.34+0.07 (+0.03%) ▲|AVGO349.46-5.53 (-1.56%) ▼|AXP304.78+2.82 (+0.93%) ▲|BA197.43-2.50 (-1.25%) ▼|BAC56.15+0.15 (+0.26%) ▲|BKNG157.93+2.03 (+1.30%) ▲|BLK1,071.39+10.50 (+0.99%) ▲|BMY61.11-0.05 (-0.07%) ▼|BNY150.19+0.68 (+0.45%) ▲|BRK-B506.29-0.89 (-0.17%) ▼|C132.45+0.52 (+0.39%) ▲|CAT803.14-8.89 (-1.09%) ▼|CL85.40-0.53 (-0.62%) ▼|CMCSA22.11-0.45 (-1.97%) ▼|COF196.22+0.12 (+0.06%) ▲|COP129.42+1.33 (+1.04%) ▲|COST898.42-6.28 (-0.69%) ▼|CRM239.01+1.43 (+0.60%) ▲|CSCO106.41-0.02 (-0.02%) ▼|CVS84.88-0.99 (-1.15%) ▼|CVX206.10+0.59 (+0.28%) ▲|DE694.10-15.38 (-2.17%) ▼|DHR223.82+2.26 (+1.02%) ▲|DIS105.47+2.01 (+1.94%) ▲|DUK113.67-0.50 (-0.44%) ▼|EMR155.84+1.25 (+0.81%) ▲|FDX279.91-11.59 (-3.98%) ▼|GD338.65-4.68 (-1.36%) ▼|GE320.82+1.02 (+0.32%) ▲|GEV955.22+3.40 (+0.36%) ▲|GILD149.79-1.58 (-1.04%) ▼|GM80.23-3.54 (-4.23%) ▼|GOOG338.17+3.19 (+0.95%) ▲|GOOGL342.12+4.29 (+1.27%) ▲|GS923.31-13.05 (-1.39%) ▼|HD291.75-4.97 (-1.68%) ▼|HON211.39-1.18 (-0.56%) ▼|IBM227.26-5.51 (-2.37%) ▼|INTC127.10+4.50 (+3.67%) ▲|INTU277.01-9.80 (-3.42%) ▼|ISRG399.39+1.09 (+0.27%) ▲|JNJ271.70+2.53 (+0.94%) ▲|JPM338.18+0.65 (+0.19%) ▲|KO88.35+0.26 (+0.29%) ▲|LIN466.74-2.99 (-0.64%) ▼|LLY1,190.37+39.38 (+3.42%) ▲|LMT525.62+0.94 (+0.18%) ▲|LOW188.12-3.25 (-1.70%) ▼|LRCX305.72-1.57 (-0.51%) ▼|MA565.74+5.82 (+1.04%) ▲|MCD237.77-0.55 (-0.23%) ▼|MDLZ60.92-0.53 (-0.85%) ▼|MDT88.57-0.73 (-0.82%) ▼|META778.37+34.27 (+4.61%) ▲|MMM167.46-2.84 (-1.67%) ▼|MO68.93-0.03 (-0.04%) ▼|MRK148.68+0.60 (+0.41%) ▲|MS196.48-1.91 (-0.96%) ▼|MSFT497.85-2.74 (-0.55%) ▼|MU1,076.71+4.83 (+0.45%) ▲|NEE75.91-1.11 (-1.44%) ▼|NFLX71.71+0.35 (+0.48%) ▲|NKE35.89-0.16 (-0.45%) ▼|NOW138.27-2.51 (-1.78%) ▼|NVDA223.62-1.90 (-0.84%) ▼|ORCL139.42-5.14 (-3.56%) ▼|PEP128.26-1.92 (-1.47%) ▼|PFE28.41+0.23 (+0.80%) ▲|PG146.17-1.22 (-0.83%) ▼|PLTR192.26+0.47 (+0.24%) ▲|PM191.60+0.76 (+0.40%) ▲|QCOM194.74-2.51 (-1.27%) ▼|RTX188.66-3.53 (-1.84%) ▼|SBUX93.56-0.59 (-0.62%) ▼|SCHW99.50-0.01 (-0.01%) ▼|SO82.97-0.50 (-0.60%) ▼|SPG204.61+0.45 (+0.22%) ▲|T25.45+0.15 (+0.57%) ▲|TMO682.05+16.75 (+2.52%) ▲|TMUS165.36-0.30 (-0.18%) ▼|TSLA379.60-0.53 (-0.14%) ▼|TXN270.84-1.79 (-0.65%) ▼|UBER69.23-0.20 (-0.28%) ▼|UNH374.90+3.61 (+0.97%) ▲|UNP273.98-1.56 (-0.56%) ▼|UPS91.90-3.92 (-4.09%) ▼|USB58.40-0.09 (-0.15%) ▼|V367.79+6.27 (+1.73%) ▲|VZ47.30+0.78 (+1.67%) ▲|WFC82.11+0.21 (+0.26%) ▲|WMT107.60-2.94 (-2.66%) ▼|XOM161.91+0.68 (+0.42%) ▲|AAPL337.28+0.26 (+0.08%) ▲|ABBV265.27+0.19 (+0.07%) ▲|ABT101.11-2.38 (-2.30%) ▼|ACN178.00-5.52 (-3.01%) ▼|ADBE238.12-2.57 (-1.07%) ▼|AMAT473.60-0.79 (-0.17%) ▼|AMD627.90+13.29 (+2.16%) ▲|AMGN407.83+1.74 (+0.43%) ▲|AMT168.27-2.52 (-1.47%) ▼|AMZN249.34+0.07 (+0.03%) ▲|AVGO349.46-5.53 (-1.56%) ▼|AXP304.78+2.82 (+0.93%) ▲|BA197.43-2.50 (-1.25%) ▼|BAC56.15+0.15 (+0.26%) ▲|BKNG157.93+2.03 (+1.30%) ▲|BLK1,071.39+10.50 (+0.99%) ▲|BMY61.11-0.05 (-0.07%) ▼|BNY150.19+0.68 (+0.45%) ▲|BRK-B506.29-0.89 (-0.17%) ▼|C132.45+0.52 (+0.39%) ▲|CAT803.14-8.89 (-1.09%) ▼|CL85.40-0.53 (-0.62%) ▼|CMCSA22.11-0.45 (-1.97%) ▼|COF196.22+0.12 (+0.06%) ▲|COP129.42+1.33 (+1.04%) ▲|COST898.42-6.28 (-0.69%) ▼|CRM239.01+1.43 (+0.60%) ▲|CSCO106.41-0.02 (-0.02%) ▼|CVS84.88-0.99 (-1.15%) ▼|CVX206.10+0.59 (+0.28%) ▲|DE694.10-15.38 (-2.17%) ▼|DHR223.82+2.26 (+1.02%) ▲|DIS105.47+2.01 (+1.94%) ▲|DUK113.67-0.50 (-0.44%) ▼|EMR155.84+1.25 (+0.81%) ▲|FDX279.91-11.59 (-3.98%) ▼|GD338.65-4.68 (-1.36%) ▼|GE320.82+1.02 (+0.32%) ▲|GEV955.22+3.40 (+0.36%) ▲|GILD149.79-1.58 (-1.04%) ▼|GM80.23-3.54 (-4.23%) ▼|GOOG338.17+3.19 (+0.95%) ▲|GOOGL342.12+4.29 (+1.27%) ▲|GS923.31-13.05 (-1.39%) ▼|HD291.75-4.97 (-1.68%) ▼|HON211.39-1.18 (-0.56%) ▼|IBM227.26-5.51 (-2.37%) ▼|INTC127.10+4.50 (+3.67%) ▲|INTU277.01-9.80 (-3.42%) ▼|ISRG399.39+1.09 (+0.27%) ▲|JNJ271.70+2.53 (+0.94%) ▲|JPM338.18+0.65 (+0.19%) ▲|KO88.35+0.26 (+0.29%) ▲|LIN466.74-2.99 (-0.64%) ▼|LLY1,190.37+39.38 (+3.42%) ▲|LMT525.62+0.94 (+0.18%) ▲|LOW188.12-3.25 (-1.70%) ▼|LRCX305.72-1.57 (-0.51%) ▼|MA565.74+5.82 (+1.04%) ▲|MCD237.77-0.55 (-0.23%) ▼|MDLZ60.92-0.53 (-0.85%) ▼|MDT88.57-0.73 (-0.82%) ▼|META778.37+34.27 (+4.61%) ▲|MMM167.46-2.84 (-1.67%) ▼|MO68.93-0.03 (-0.04%) ▼|MRK148.68+0.60 (+0.41%) ▲|MS196.48-1.91 (-0.96%) ▼|MSFT497.85-2.74 (-0.55%) ▼|MU1,076.71+4.83 (+0.45%) ▲|NEE75.91-1.11 (-1.44%) ▼|NFLX71.71+0.35 (+0.48%) ▲|NKE35.89-0.16 (-0.45%) ▼|NOW138.27-2.51 (-1.78%) ▼|NVDA223.62-1.90 (-0.84%) ▼|ORCL139.42-5.14 (-3.56%) ▼|PEP128.26-1.92 (-1.47%) ▼|PFE28.41+0.23 (+0.80%) ▲|PG146.17-1.22 (-0.83%) ▼|PLTR192.26+0.47 (+0.24%) ▲|PM191.60+0.76 (+0.40%) ▲|QCOM194.74-2.51 (-1.27%) ▼|RTX188.66-3.53 (-1.84%) ▼|SBUX93.56-0.59 (-0.62%) ▼|SCHW99.50-0.01 (-0.01%) ▼|SO82.97-0.50 (-0.60%) ▼|SPG204.61+0.45 (+0.22%) ▲|T25.45+0.15 (+0.57%) ▲|TMO682.05+16.75 (+2.52%) ▲|TMUS165.36-0.30 (-0.18%) ▼|TSLA379.60-0.53 (-0.14%) ▼|TXN270.84-1.79 (-0.65%) ▼|UBER69.23-0.20 (-0.28%) ▼|UNH374.90+3.61 (+0.97%) ▲|UNP273.98-1.56 (-0.56%) ▼|UPS91.90-3.92 (-4.09%) ▼|USB58.40-0.09 (-0.15%) ▼|V367.79+6.27 (+1.73%) ▲|VZ47.30+0.78 (+1.67%) ▲|WFC82.11+0.21 (+0.26%) ▲|WMT107.60-2.94 (-2.66%) ▼|XOM161.91+0.68 (+0.42%) ▲|
18.7 C
New York
Thursday, September 24, 2026

Tag: FOR

newssourceFORcompanyinformationcontent1releasesmarket

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Resultater fra Ultimovacs’ DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den NSGO-CTU sponsede fase II DOVACC kliniske studie (NCT04742075) som testet Ultimovacs' UV1 kreftvaksine ikke oppnådde sitt primære endepunkt om å forbedre progresjonsfri overlevelse (PFS). UV1 ble overtatt gjennom virksomhetssammenslåingen mellom de to selskapene i 2025. Dette avslutter den tidligere kommuniserte avviklingsfasen av UV1-kreftvaksine-programmet, og Zelluna anser nå programmet som avsluttet.

Minister Hodgson accelerates Canada’s mining sector

YELLOWKNIFE, NT, June 26, 2026 /CNW/ - Canada has what the world wants and is acting with urgency to unlock the full potential of...

Group 1 Automotive Announces Honda of Owings Mills is now Group 1 Honda Owings Mills

Former Honda of Owings Mills location continues serving Owings Mills and Baltimore County customers under the Group 1 Honda Owings Mills nameOWINGS MILLS, Md.,...

Group 1 Automotive Announces Honda of Greenbelt is now Group 1 Honda Greenbelt

Former Honda of Greenbelt location continues serving Greenbelt and Prince George's County customers under the Group 1 Honda Greenbelt nameGREENBELT, Md., June 26, 2026...

Group 1 Automotive Announces Toyota Certified at Capital Plaza is now Group 1 Toyota Certified Capital Plaza

Former Toyota Certified at Capital Plaza location continues serving Landover Hills and Prince George's County customers under the Group 1 Toyota Certified Capital Plaza...

FIA Delivers Strongest Set of Financial Results in a Decade

FIA posts best financial results in a decade: €6.7M operating profit in 2025, revenues of €191.7M, and cash doubled to €43.6M

TRULY HARD SELTZER BETS $5 MILLION THAT U.S. SOCCER WILL WIN IT ALL, AND GIVES ONE FAN THE CHANCE TO CASH IN

The Official Hard Seltzer of U.S. Soccer is offering what’s believed to be the largest single fan prize ever tied to American soccer, paying one believer $5 million if the U.S. Men’s National Team wins it all 
The Official Hard Seltzer of U.S. Soccer is offering what’s believed to be the largest single fan prize ever tied to American soccer, paying one believer $5 million if the U.S. Men’s National Team wins it all

Affordable Luxury Summer Sale Brings Cate & Chloe to Walmart Summer Deals Event

Phoenix, ARIZONA, June 26, 2026 (GLOBE NEWSWIRE) -- An affordable luxury summer sale from Cate & Chloe is set to launch alongside Walmart’s upcoming Summer Deals Event. The brand has announced that its Eden 18k White Gold Plated Crystal Stud Earrings will be available for $16.99, down from a $77 MSRP.

Major Shareholder Announcement

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets

MUMBAI, India and NAPLES, Fla., June 26, 2026 /CNW/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN)...

Air Products Publishes 2026 Sustainability Report

LEHIGH VALLEY, Pa., June 26, 2026 /PRNewswire/ -- Air Products (NYSE: APD) today published its 2026 Sustainability Report. The report provides stakeholders with economic,...

The Doctors Company Completes Acquisition of ProAssurance Corporation

NAPA, Calif., June 26, 2026 /PRNewswire/ -- The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has completed the acquisition...

The World Cup Is Bringing North America Together. MADD Canada and MADD Are Uniting to Keep Fans Safe.

Organizations unite across North America to promote sober driving throughout the world's biggest sporting eventOAKVILLE, ON and IRVING, Texas, June 26, 2026 /PRNewswire/ --...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFOR

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers